On May 27, 2021 VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related antigens, reported that the Company will attend several international scientific and industry events in the coming months (Press release, Vaximm, MAY 27, 2021, View Source [SID1234583290]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Heinz Lubenau, Chief Executive Officer of VAXIMM, and the management team will participate in the following conferences:
American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2021
June 4-8, 2021, Virtual Event
• To schedule a meeting with the Company, please contact [email protected].
BIO KOREA
June 9-11, 2021, Virtual and Live Event (COEX, Seoul)
• To request a meeting with Dr. Lubenau, please sign up through the event’s online partnering system.
BIO Digital
June 10-11 & June 14-18, 2021, Virtual Event
• Company presentation.
• To request a meeting, please sign up through the event’s BIO one-on-one partnering system.
Paris Immuno-Oncology Conference
July 1-2, 2021, Virtual Event
• To schedule a meeting with the Company, please contact [email protected].
For updates, please see the Events section of the Company’s website.